{"id":323546,"date":"2024-10-29T00:00:00","date_gmt":"2024-10-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0006-2024-biopharma-renal-anemia-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:28:01","modified_gmt":"2026-03-31T10:28:01","slug":"dlsfmd0006-2024-biopharma-renal-anemia-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0006-2024-biopharma-renal-anemia-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Renal Anemia &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Renal anemia is a common complication of chronic kidney disease (<abbr data-abbreviation-entity=\"4765\" title=\"chronic kidney disease\">CKD<\/abbr>). The primary goal of treatment of renal anemia is to increase and maintain <abbr data-abbreviation-entity=\"6231\" title=\"hemoglobin\">Hb<\/abbr> levels and reduce the risk of complications of chronic hypoxia, cardiovascular disease, and mortality. The current management of renal anemia involves oral and <abbr data-abbreviation-entity=\"4871\" title=\"intravenous\">IV<\/abbr> iron formulations, <abbr data-abbreviation-entity=\"6091\" title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>s, and <abbr data-abbreviation-entity=\"6571\" title=\"hypoxia-inducible factor-prolyl hydroxylase\">HIF-PH<\/abbr> inhibitors. Although treatments are available, substantial opportunity remains for safe oral drugs that are less frequently dosed and more effective in reaching target <abbr data-abbreviation-entity=\"6231\" title=\"hemoglobin\">Hb<\/abbr> levels. The renal anemia therapy market will expand over the 2023-2033 forecast period, fueled by the uptake of <abbr data-abbreviation-entity=\"6571\" title=\"hypoxia-inducible factor-prolyl hydroxylase\">HIF-PH<\/abbr> inhibitors and increasing diagnosis and treatment rates over the forecast period. Physicians are optimistic about the <abbr data-abbreviation-entity=\"6571\" title=\"hypoxia-inducible factor-prolyl hydroxylase\">HIF-PH<\/abbr> inhibitors because they believe this class offers several benefits over conventional <abbr data-abbreviation-entity=\"6091\" title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>s, such as oral administration, lower cost, physiological levels of endogenous <abbr data-abbreviation-entity=\"5524\" title=\"erythropoietin\">EPO<\/abbr> production, and improved iron utilization efficiency.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the prevalence of renal anemia in the major pharmaceutical markets under study?<\/li>\n<li>How is renal anemia currently treated? Will <abbr data-abbreviation-entity=\"6091\" title=\"erythropoiesis-stimulating agent\">ESA<\/abbr>s maintain their strong market position, and how much pressure will they face from new entrants?<\/li>\n<li>What is the commercial potential of novel <abbr data-abbreviation-entity=\"6571\" title=\"hypoxia-inducible factor-prolyl hydroxylase\">HIF-PH<\/abbr> inhibitors? How do nephrologists rate these drug candidates?<\/li>\n<li>Will establishing cardiovascular (<abbr data-abbreviation-entity=\"4781\" title=\"cardiovascular\">CV<\/abbr>) safety be key for the market uptake of <abbr data-abbreviation-entity=\"6571\" title=\"hypoxia-inducible factor-prolyl hydroxylase\">HIF-PH<\/abbr> inhibitors, in view of the <abbr data-abbreviation-entity=\"4781\" title=\"cardiovascular\">CV<\/abbr> issues associated with current therapies?<\/li>\n<li>How will the renal anemia market evolve over the next 10 years?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan<\/li>\n<li><strong>Primary research: <\/strong>19 country-specific interviews with thought-leading nephrologists; supported by survey data collected for this and other Clarivate research<\/li>\n<li><strong>Epidemiology:<\/strong><strong> <\/strong> Prevalence of renal anemia by country and diagnosed \/ drug-treated rates<\/li>\n<li><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies<\/li>\n<li><strong>Market forecast features: <\/strong>10-year, annualized, drug-level sales and patient share of key renal anemia therapies through 2033, segmented by brands \/ generics<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><b>Key features<\/b><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p><!--[if pub]><xml><b:Publication type=\"OplPub\" oty=\"68\" oh=\"256\"><b:OhPrintBlock priv=\"30E\">281<\/b:OhPrintBlock><b:DptlPageDimensions type=\"OplPt\" priv=\"1211\"><b:Xl priv=\"104\">7772400<\/b:Xl><b:Yl priv=\"204\">10058400<\/b:Yl><\/b:DptlPageDimensions><b:OhGallery priv=\"180E\">259<\/b:OhGallery><b:OhFancyBorders priv=\"190E\">261<\/b:OhFancyBorders><b:OhCaptions priv=\"1A0E\">257<\/b:OhCaptions><b:OhQuillDoc priv=\"200E\">276<\/b:OhQuillDoc><b:OhMailMergeData priv=\"210E\">262<\/b:OhMailMergeData><b:OhColorScheme priv=\"220E\">279<\/b:OhColorScheme><b:DwNextUniqueOid priv=\"2304\">1<\/b:DwNextUniqueOid><b:IdentGUID priv=\"2A07\">0``````````````````````<\/b:IdentGUID><b:DpgSpecial priv=\"2C03\">5<\/b:DpgSpecial><b:FWorkpaneVisible priv=\"3900\">False<\/b:FWorkpaneVisible><b:CTimesEdited priv=\"3C04\">1<\/b:CTimesEdited><b:NuDefaultUnitsEx priv=\"4104\">0<\/b:NuDefaultUnitsEx><b:OhImpositionEngine priv=\"440E\">285<\/b:OhImpositionEngine><\/b:Publication><b:PrinterInfo type=\"OplPrb\" oty=\"75\" oh=\"281\"><b:OhColorSepBlock priv=\"30E\">282<\/b:OhColorSepBlock><b:FKOBlackFills priv=\"A00\">True<\/b:FKOBlackFills><b:OpmOutsidePrintMode priv=\"B04\">1<\/b:OpmOutsidePrintMode><b:FInitComplete priv=\"1400\">False<\/b:FInitComplete><b:DpiX priv=\"2203\">0<\/b:DpiX><b:DpiY priv=\"2303\">0<\/b:DpiY><b:DxlOverlap priv=\"2404\">0<\/b:DxlOverlap><b:DylOverlap priv=\"2504\">0<\/b:DylOverlap><\/b:PrinterInfo><b:ColorSeperationInfo type=\"OplCsb\" oty=\"79\" oh=\"282\"><b:Plates type=\"OplCsp\" priv=\"214\"><b:OplCsp type=\"OplCsp\" priv=\"11\"><b:EcpPlate type=\"OplEcp\" priv=\"213\"><b:Color priv=\"104\">-1<\/b:Color><\/b:EcpPlate><\/b:OplCsp><\/b:Plates><b:DzlOverprintMost priv=\"304\">304800<\/b:DzlOverprintMost><b:CprOverprintMin priv=\"404\">243<\/b:CprOverprintMin><b:DzlTrap priv=\"C04\">3175<\/b:DzlTrap><b:DzlIndTrap priv=\"D04\">3175<\/b:DzlIndTrap><b:PctCenterline priv=\"E04\">70<\/b:PctCenterline><b:FMarksRegistration priv=\"F00\">True<\/b:FMarksRegistration><b:FMarksJob priv=\"1000\">True<\/b:FMarksJob><b:FMarksDensity priv=\"1100\">True<\/b:FMarksDensity><\/b:ColorSeperationInfo><b:TextDocProperties type=\"OplDocq\" oty=\"91\" oh=\"276\"><b:OhPlcqsb priv=\"20E\">278<\/b:OhPlcqsb><b:EcpSplitMenu type=\"OplEcp\" priv=\"A13\"><b:Color>134217728<\/b:Color><\/b:EcpSplitMenu><\/b:TextDocProperties><b:StoryBlock type=\"OplPlcQsb\" oty=\"101\" oh=\"278\"><b:IqsbMax priv=\"104\">1<\/b:IqsbMax><b:Rgqsb type=\"OplQsb\" priv=\"214\"><b:OplQsb type=\"OplQsb\" priv=\"11\"><b:Qsid priv=\"104\">2<\/b:Qsid><b:TomfCopyfitBase priv=\"80B\">-9999996.000000<\/b:TomfCopyfitBase><b:TomfCopyfitBase2 priv=\"90B\">-9999996.000000<\/b:TomfCopyfitBase2><\/b:OplQsb><\/b:Rgqsb><\/b:StoryBlock><b:ColorScheme type=\"OplSccm\" oty=\"92\" oh=\"279\"><b:Cecp priv=\"104\">8<\/b:Cecp><b:Rgecp type=\"OplEcp\" priv=\"214\"><b:OplEcp priv=\"F\">Empty<\/b:OplEcp><b:OplEcp type=\"OplEcp\" priv=\"111\"><b:Color>7743603<\/b:Color><\/b:OplEcp><b:OplEcp type=\"OplEcp\" priv=\"211\"><b:Color>4958229<\/b:Color><\/b:OplEcp><b:OplEcp type=\"OplEcp\" priv=\"311\"><b:Color>13208129<\/b:Color><\/b:OplEcp><b:OplEcp type=\"OplEcp\" priv=\"411\"><b:Color>7109876<\/b:Color><\/b:OplEcp><b:OplEcp type=\"OplEcp\" priv=\"511\"><b:Color>4049302<\/b:Color><\/b:OplEcp><b:OplEcp type=\"OplEcp\" priv=\"611\"><b:Color>2207729<\/b:Color><\/b:OplEcp><b:OplEcp type=\"OplEcp\" priv=\"711\"><b:Color>4049302<\/b:Color><\/b:OplEcp><\/b:Rgecp><b:IScheme priv=\"304\">2000<\/b:IScheme><b:SzSchemeName priv=\"618\">DRG<\/b:SzSchemeName><\/b:ColorScheme><![if pub11]><![endif]><\/xml><![endif]--><!--[if pub]><xml><b:Page type=\"OplPd\" oty=\"67\" oh=\"265\"><b:PtlvOrigin type=\"OplPt\" priv=\"511\"><b:Xl>22860000<\/b:Xl><b:Yl>22860000<\/b:Yl><\/b:PtlvOrigin><b:Oid priv=\"605\">(`@`````````<\/b:Oid><b:OhoplWebPageProps priv=\"90E\">266<\/b:OhoplWebPageProps><b:OhpdMaster priv=\"D0D\">263<\/b:OhpdMaster><b:PgtType priv=\"1004\">5<\/b:PgtType><b:PtlvOriginEx type=\"OplPt\" priv=\"1111\"><b:Xl>110185200<\/b:Xl><b:Yl>110185200<\/b:Yl><\/b:PtlvOriginEx><\/b:Page><\/xml><![endif]--><!--[if gte mso 9]><xml><o:shapedefaults v:ext=\"edit\" spidmax=\"3075\" fillcolor=\"#732876 [1]\"\n  strokecolor=\"black [0]\"><v:fill color=\"#732876 [1]\" color2=\"#96c93d [7]\"\/><v:stroke color=\"black [0]\" color2=\"#96c93d [7]\" weight=\"2pt\"><o:left v:ext=\"view\" color=\"black [0]\" color2=\"#96c93d [7]\"\/><o:top v:ext=\"view\" color=\"black [0]\" color2=\"#96c93d [7]\"\/><o:right v:ext=\"view\" color=\"black [0]\" color2=\"#96c93d [7]\"\/><o:bottom v:ext=\"view\" color=\"black [0]\" color2=\"#96c93d [7]\"\/><o:column v:ext=\"view\" color=\"black [0]\" color2=\"#96c93d [7]\"\/><\/v:stroke><v:shadow color=\"black [0]\"\/><o:extrusion v:ext=\"view\" backdepth=\"0\" viewpoint=\"0,0\" viewpointorigin=\"0,0\"\/><v:textbox inset=\"2.88pt,2.88pt,2.88pt,2.88pt\"\/><o:colormenu v:ext=\"edit\" fillcolor=\"#732876 [1]\" strokecolor=\"black [0]\"\n   shadowcolor=\"#f47c6c [4]\"\/><\/o:shapedefaults><o:shapelayout v:ext=\"edit\"><o:idmap v:ext=\"edit\" data=\"1\"\/><\/o:shapelayout><\/xml><![endif]--><\/p>\n","protected":false},"template":"","class_list":["post-323546","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-renal-anemia","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/323546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/323546\/revisions"}],"predecessor-version":[{"id":575896,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/323546\/revisions\/575896"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=323546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}